Vaccines that facilitate antigen entry into dendritic cells

Immunology and Cell Biology

Volumn 82, Issue 5, 2004, Pages 506-516

  Gamvrellis, Anita ^a   Leong, David ^a   Hanley, Jennifer C ^a   Xiang, Sue D ^a   Mottram, Patricia ^a   Plebanski, Magdalena ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Dendritic cells; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; FLT3 LIGAND; HEAT SHOCK PROTEIN; LATEX; LENTIVIRUS VECTOR; LIPOPOLYSACCHARIDE; POLYSTYRENE;

ANTIGEN PRESENTING CELL; CELL ACTIVATION; DENDRITIC CELL; DIPHTHERIA; DRUG FORMULATION; DRUG STORAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; MALARIA; NONHUMAN; POLIOMYELITIS; REVIEW; SIGNAL TRANSDUCTION; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS; DENDRITIC CELLS; HUMANS; VACCINES;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 7044251994     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01271.x     Document Type: Review

References (150)

1. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 1999; 5: 1249-55.
2. Apostolopoulos V, Plebanski M. The evolution of DNA vaccines. Curr. Opin. Mol. Ther. 2000; 2: 441-7.
3. Jeannin P, Renno T, Goetsch L et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 2000; 1: 502-9.
4. Maraskovsky E, Daro E, Roux E et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878-84.
5. Allsopp CE, Plebanski M, Gilbert S et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 1996; 26: 1951-9.
6. Gilbert SC, Plebanski M, Harris SJ et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 1997; 15: 1280-4.
7. Furrie E, Smith RE, Turner MW, Strobel S, Mowat AM. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 2002; 20: 2254-62.
8. Singh M, O'Hagan DT. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 2003; 33: 469-78.
9. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-6.
10. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000; 18: 927-74.
11. McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE. Aspects of cancer immunotherapy. Immunol. Cell Biol. 2003; 81: 79-85.
12. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996; 5: 295-302.
13. Ramachandra L, Chu RS, Askew D et al. Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunol. Rev. 1999; 168: 217-39.
14. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 1998; 16: 1025-31.
15. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J. Immunol. 2001; 166: 5327-30.
16. Stockwin LH, McGonagle D, Martin IG, Blair GE. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol. Cell Biol. 2000; 78: 91-102.
17. den Haan JM, Lehar SM, Bevan MJ. CD8 (+) but not CD8 (-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp Med. 2000; 192: 1685-96.
18. Schulz O, Pennington DJ, Hodivala-Dilke K, Febbraio M, Reis e Sousa C. CD36 or alphavbeta3 and alphavbeta5 integrins are not essential for MHC class I cross-presentation of cell-associated antigen by CD8 alpha+ murine dendritic cells. J. Immunol. 2002; 168: 6057-65.
19. Belz GT, Vremec D, Febbraio M et al. CD36 is differentially expressed by CD8+ splenic dendritic cells but is not required for cross-presentation in vivo. J. Immunol. 2002; 168: 6066-70.
20. Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 2004; 103: 2187-95.
21. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 2000; 164: 2978-86.
22. De Smedt T, Pajak B, Muraille E et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 1996; 184: 1413-24.
23. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
24. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003; 21: 335-76.
25. Murphy EE, Terres G, Macatonia SE et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to b7 costimulation. J. Exp. Med. 1994; 180: 223-31.
26. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996; 183: 87-97.
27. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999; 5: 919-23.
28. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835-7.
29. Poeck H, Wagner M, Battiany J et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004; 103: 3058-64.
30. Asselin-Paturel C, Boonstra A, Dalod M et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2001; 2: 1144-50.
31. Nakano H, Yanagita M, Gunn MD. CD11c (+) B220 (+) Gr-1 (+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 2001; 194: 1171-8.
32. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr. Opin. Immunol. 2000; 12: 114-21.
33. Mahnke K, Guo M, Lee S et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 2000; 151: 673-84.
34. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002; 196: 1627-38.
35. Kochman S, Bernard J. Antitumour immune response and cancer vaccination: the critical role of dendritic cells. Curr. Med. Res. Opin. 1999; 15: 321-6.
36. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
37. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 1996; 183: 283-7.
38. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995; 1: 1297-302.
39. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 1998; 95: 9482-7.
40. Imro MA, Manici S, Russo V et al. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen (s). Cancer Res. 1999; 59: 2287-91.
41. Schulz O, Reis e Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002; 107: 183-9.
42. Desai J, Mitchell PL, Loveland BE et al. A phase I trial of dendritic cells pulsed with MUC1 peptide in patients with solid tumours. Proc. ASCO 2002; 21: 1868.
43. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999; 190: 1669-78.
44. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 2001; 166: 4254-9.
45. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000; 18: 3174-84.
46. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 2001; 98: 8809-14.
47. Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 1999; 163: 3668-75.
48. Pisarev VM, Parajuli P, Mosley RL et al. Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. Vaccine 2002; 20: 2358-68.
49. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 2000; 60: 3239-46.
50. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 2000; 1: 151-5.
51. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 2000; 12: 1539-46.
52. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge, heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol. 2000; 165: 6029-35.
53. Singh-Jasuja H, Scherer HU, Hilf N et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 2000; 30: 2211-5.
54. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13.
55. Singh-Jasuja H, Toes RE, Spee P et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 2000; 191: 1965-74.
56. Zheng H, Dai J, Stoilova D, Li Z. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and anti-tumor immunity. J. Immunol. 2001; 167: 6731-5.
57. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Meth. 1999; 223: 77-92.
58. Altmeyer A, Maki RG, Feldweg AM et al. Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int. J. Cancer 1996; 69: 340-9.
59. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 1994; 152: 5398-403.
60. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein presss. Science 1997; 278: 117-20.
61. Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 1997; 57: 69-74.
62. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585-8.
63. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Anna. Rev. Immunol. 2002; 20: 709-60.
64. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001; 2: 675-80.
65. Coombes BK, Mahony JB. Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. Immunol. Lett. 2001; 78: 103-11.
66. Rhee EG, Mendez S, Shah JA et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J. Exp. Med. 2002; 195: 1565-73.
67. Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 1997; 186: 1137-47.
68. Shah JA, Darrah PA, Ambrozak DR et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 2003; 198: 281-91.
69. Sebo P, Darrah PA, Ambrozak DR et al. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8 (+) T-cell epitope. FEMS Immunol. Med. Microbiol. 1999; 26: 167-73.
70. Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J. Immunol. 1996; 156: 4697-706.
71. Fayolle C, Osickova A, Osicka R et al. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J. Virol. 2001; 75: 7330-8.
72. Saron MF, Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl Acad. Sci. USA 1997; 94: 3314-9.
73. Guermonprez P, Khelef N, Blouin E et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha (M) beta (2) integrin (CD11b/CD18). J. Exp. Med. 2001; 193: 1035-44.
74. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. 2003; 106: 231-7.
75. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur. J. Immunol. 1998; 28: 1401-7.
76. Roth JF. The yeast Ty virus-like particles. Yeast 2000; 16: 785-95.
77. Pumpens P, Borisova GP, Crowther RA, Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology 1995; 38: 63-74.
78. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996; 7: 373-82.
79. Warfield KL, Bosio CM, Welcher BC et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl Acad. Sci. USA 2003; 100: 15889-94.
80. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 2001; 108: 415-23.
81. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol 2001; 166: 5917-24.
82. Lenz P, Day PM, Pang YY et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 2001; 166: 5346-55.
83. Pumpens P, Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett. 1999; 442: 1-6.
84. Riedl P, Stober D, Oehninger C, Melber K, Reimann J, Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 2002; 168: 4951-9.
85. Bohm W, Schirmbeck R, Elbe A et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J. Immunol. 1995; 155: 3313-21.
86. Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J. Immunol. 1995; 155: 4676-84.
87. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel non-replicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl Acad. Sci. USA 1997; 94: 7503-8.
88. Moron VG, Rueda P, Casal I, Leclerc C. CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J. Exp Med. 2002; 195: 1233-45.
89. Sedlik C, Dadaglio G, Saron MF et al. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J. Virol. 2000; 74: 5769-75.
90. Grassi F, Hosmalin A, McIlroy D, Calvez V, Debre P, Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. Aids 1999; 13: 759-66.
91. Lore K, Sonnerborg A, Brostrom C et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. Aids 2002; 16: 683-92.
92. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M et al. Yeast-derived human immunodeficiency virus type 1 p55 (gag) virus-like particles activate dendritic cells (DCs) and induce perform expression in Gag-specific CD8 (+) T cells by cross-presentation of DCs. J. Virol. 2003; 77: 10250-9.
93. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 2000; 16: 273-82.
94. Wang C, Ge Q, Ting D et al. Molecularly engineered poly (ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater. 2004; 3: 190-6.
95. Langer R, Cleland JL, Hanes J. New advances in microsphere-based single-dose vaccines. Adv. Drug Deliv. Rev. 1997; 28:97-119.
96. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 1998; 4: 365-8.
97. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA 2000; 97: 811-6.
98. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11: 753-61.
99. Audran R, Peter K, Dannull J et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003; 21: 1250-5.
100. Men Y, Audran R, Thomasin C et al. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 1999; 17: 1047-56.
101. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 1997; 158: 2723-30.
102. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
103. Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-80.
104. Cho HJ, Takabayashi K, Cheng PM et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 2000; 18: 509-14.
105. Dubensky TW Jr, Liu MA, Ulmer JB. Delivery systems for gene-based vaccines. Mol. Med. 2000; 6: 723-32.
106. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999; 17: 1075-81.
107. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 2000; 17: 100-6.
108. Sinha RK, Khuller GK. The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice. Immunol. Cell Biol. 1997; 75: 461-6.
109. Lachman LB, Ozpolat B, Rao XM. Cytokine-containing liposomes as vaccine adjuvants. Eur. Cytokine Netw. 1996; 7: 693-8.
110. Okada E, Sasaki S, Ishii N et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF) -expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 1997; 159: 3638-47.
111. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-13.
112. Okamoto T, Kaneda Y, Yuzuki D, Huang SK, Chi DD, Hoon DS. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther. 1997; 4: 969-76.
113. Kwak LW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol. 1998;160:3637-41.
114. Alving CR. Liposomes as carriers of antigens and adjuvants. J. Immunol. Meth. 1991; 140: 1-13.
115. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77-80.
116. Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8 (+) T cells in vivo: implications for adaptive immunotherapy. Eur. J. Immunol. 2001; 31: 1772-9.
117. Sjolander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19: 2661-5.
118. Watson DL, Lovgren K, Watson NA, Fossum C, Morein B, Hoglund S. Inflammatory response and antigen localization following immunization with influenza virus ISCOMs. Inflammation 1989; 13: 641-9.
119. Robson NC, Beacock-Sharp H, Donachie AM, Mowat AM. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 2003, 1989; 110: 95-104.
120. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988; 27: 241-5.
121. Lovgren-Bengtsson K, Morein, B. The ISCOM™ Technology. In: O'Hagan D (ed.) Vaccine Adjuvants: Preparation Methods and Research Protocols. Humana Press: Totowa, 2000; 239-58.
122. Borchard G. Chitosans for gene delivery. Adv. Drug Deliv. Rev. 2001, 2000; 52: 145-50.
123. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 1999; 5: 387-91.
124. Kumar M, Behera AK, Lockey RF et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 2002; 13: 1415-25.
125. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 1993; 90: 4942-6.
126. Song R, Harding CV. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J. Immunol. 1996; 156: 4182-90.
127. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J. Immunol. 1996; 156: 2809-18.
128. Forestier J. Rheumatoid arthritis and its treatment by gold salts. J. Laboratoryclin. Med. 1935; 20: 827-30.
129. Dietrich G. Current status and future perspectives of DNA vaccine delivery by attenuated intracellular bacteria. Arch. Immunol. Ther. Exp. (Warsz). 2000; 48: 177-82.
130. Mumper RJ, Ledebur HC Jr. Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization. Mol. Biotechnol. 2001; 19: 79-95.
131. Pavelic K, Hadzija M, Bedrica L et al. Natural zeolite clinoptilolite: new adjuvant in anticancer therapy. J. Mol. Med. 2001; 78: 708-20.
132. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1995; 1: 649-53.
133. Kruth HS, Chang J, Ifrim I, Zhang WY. Characterization of patocytosis: endocytosis into macrophage surface-connected compartments. Eur. J. Cell Biol. 1999; 78: 91-9.
134. Thalhamer J, Leitner W, Hammerl P, Brtko J. Designing immune responses with genetic immunization and immunostimulatory DNA sequences. Endocr. Regul. 2001; 35: 143-66.
135. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol. Lett. 2002; 80: 89-96.
136. Bachtiar EW, Sheng KC, Fifis T et al. Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol. Lett. 2003; 227: 211-7.
137. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 2001; 22: 102-7.
138. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J. Control. Release 2004; 94: 1-14.
139. Cusi MG, Terrosi C, Savellini GG, Di Geneva G, Zurbriggen R, Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 2004; 22: 735-9.
140. Strobel I, Krumbholz M, Menke A et al. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Hum. Gene Ther. 2000; 11: 2207-18.
141. Schneider J, Gilbert SC, Hannan CM et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 1999; 170: 29-38.
142. Hill AV, Reece W, Gothard P et al. DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. Dev. Biol. (Basel) 2000; 104: 171-9.
143. Stratov I, DeRose R, Purcell D, Kent S. Vaccines and vaccine strategies against HIV. Curr. Drug Targets 2004; 5: 71-88.
144. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003; 9: 729-35.
145. Brown KN. Antigenic diversity, antigenic variation and merozoite surface protein 1. Parassitologia 1993; 35: 13-5.
146. Gilbert SC, Plebanski M, Gupta S et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998; 279: 1173-7.
147. Roberts DJ, Craig AG, Berendt AR et al. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 1992; 357: 689-92.
148. Plebanski M, Proudfoot O, Pouniotis D, Coppel RL, Apostolopoulos V, Flannery G. Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J. Clin. Invest. 2002; 110: 295-301.
149. Plebanski M, Hill AV. The immunology of malaria infection. Curr. Opin. Immunol. 2000; 12: 437-41.
150. Urban BC, Ferguson DJ, Pain A et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400: 73-7.